Hepatitis C in special patient cohorts: New opportunities in decompensated liver cirrhosis, end-stage renal disease and transplant medicine

International Journal of Molecular Sciences

Volumn 16, Issue 8, 2015, Pages 18033-18053

  Hüsing, Anna ^a   Kabar, Iyad ^a   Schmidt, Hartmut H ^a   Heinzow, Hauke S ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Chronic kidney disease; DAA treatment; Decompensated liver cirrhosis; HCV infection; Liver transplantation; New therapy regimen; Renal transplantation

Indexed keywords

DACLATASVIR; DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; ELBASVIR PLUS GRAZOPREVIR; LEDIPASVIR; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; ANTIVIRUS AGENT;

CHRONIC KIDNEY DISEASE; DECOMPENSATED LIVER CIRRHOSIS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; END STAGE RENAL DISEASE; GENOTYPE; HEPATITIS C; LIVER TRANSPLANTATION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; RECURRENT DISEASE; REVIEW; RISK FACTOR; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; COMPLICATION; DRUG EFFECTS; HEPACIVIRUS; HUMAN; KIDNEY TRANSPLANTATION; LIVER CIRRHOSIS;

HEPATITIS C VIRUS;

ANTIVIRAL AGENTS; COHORT STUDIES; HEPACIVIRUS; HEPATITIS C; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; RECURRENCE; RENAL INSUFFICIENCY, CHRONIC;

EID: 84938842278     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms160818033     Document Type: Review

References (50)

1. Hill, A.; Saleem, J.; Heath, K.; Simmons, B. Effects of sustained virological response (SVR) on the risk of liver transplant, hepatocellular carcinoma, death and re-infection: Meta-analysis of 129 studies in 23,309 patients with Hepatitis C infection. In Proceedings of the AASLD 2014, Boston, MA, USA, 7-11 November 2014.
2. Burgess, S.; Partovi, N.; Yoshida, E.M.; Erb, S.R.; Azalgara, V.M.; Hussaini, T. Drug interactions with direct-acting antivirals for hepatitis C: Implications for HIV and transplant patients. Ann. Pharmacother. 2015, 49, 674-687.
3. Tsui, J.I.; Vittinghoff, E.; Shlipak, M.G.; Bertenthal, D.; Inadomi, J.; Rodriguez, R.A.; O'Hare, A.M. Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease. Arch. Int. Med. 2007, 167, 1271-1276.
4. Lucas, G.M.; Jing, Y.; Sulkowski, M.; Abraham, A.G.; Estrella, M.M.; Atta, M.G.; Fine, D.M.; Klein, M.B.; Silverberg, M.J.; Gill, M.J.; et al. Hepatitis C viremia and the risk of chronic kidney disease in HIV-infected individuals. J. Infect. Dis. 2013, 208, 1240-1249.
5. Perico, N.; Cattaneo, D.; Bikbov, B.; Remuzzi, G. Hepatitis C infection and chronic renal diseases. Clin. J. Am. Soc. Nephrol. 2009, 4, 207-220.
6. Fabrizi, F.; Dixit, V.; Martin, P.; Messa, P. The evidence-based epidemiology of HCV-associated kidney disease. Int. J. Artif. Organs 2012, 35, 621-628.
7. Mathurin, P.; Mouquet, C.; Poynard, T.; Sylla, C.; Benalia, H.; Fretz, C.; Thibault, V.; Cadranel, J.F.; Bernard, B.; Opolon, P.; et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999, 29, 257-263.
8. Goffin, E.; Pirson Y.; Cornu, C.; Geubel, A.; Squifflet, J.P.; van Ypersele de Strihou, C. Outcome of HCV infection after renal transplantation. Kidney Int. 1994, 45, 551-555.
9. Pereira, B.J.; Levey, A.S. Hepatitis C virus infection in dialysis and renal transplantation. Kidney Int. 1997, 51, 981-999.
10. Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int. Suppl. 2008, 73, S1-S99.
11. Roth, D.; Gaynor, J.J.; Reddy, K.R.; Ciancio, G.; Sageshima, J.; Kupin, W.; Guerra, G.; Chen, L.; Burke, G.W., III. Effect of kidney transplantation on outcomes among patients with hepatitis C. J. Am. Soc. Nephrol. 2011, 22, 1152-1160.
12. Einollahi, B.; Hajarizadeh, B.; Bakhtiari, S.; Lesanpezeshki, M.; Khatami, M.R.; Nourbala, M.H.; Pourfarziani, V.; Alavian, S.M. Pretransplant hepatitis C virus infection and its effect on the post-transplant course of living renal allograft recipients. J. Gastroenterol. Hepatol. 2003, 18, 836-840.
13. Kokado, Y.; Takahara, S.; Ichimaru, N.; Toki, K.; Wang, J.D.; Permpongkosol, S.; Sagawa, S.; Ichikawa, Y.; Akiyama, T.; Yoshimura, N.; et al. Clinical outcome of HCV infection after renal transplantation. Transpl. Proc. 2000, 32, 1940-1943.
14. Baid-Agrawal, S.; Pascual, M.; Moradpour, D.; Frei, U.; Tolkoff-Rubin, N. Hepatitis C virus infection in haemodialysis and kidney transplant patients. Rev. Med. Virol. 2008, 18, 97-115.
15. Moghaddam, S.M.; Alavian, S.M.; Kermani, N.A. Hepatitis C and renal transplantation: A review on historical aspects and current issues. Rev. Med. Virol. 2008, 18, 375-386.
16. Gentil Govantes, M.A.; Esforzado, N.; Cruzado, J.M.; González-Roncero, F.M.; Balaña, M.; Saval, N.; Morales, J.M. Harmful effects of viral replication in seropositive hepatitis C virus renal transplant recipients. Transplantation 2012, 94, 1131-1137.
17. Baid, S.; Tolkoff-Rubin, N.; Saidman, S.; Chung, R.; Williams, W.W.; Auchincloss, H.; Colvin, R.B.; Delmonico, F.L.; Cosimi, A.B.; Pascual, M. Acute humoral rejection in hepatitis C-infected renal transplant recipients receiving antiviral therapy. Am. J. Transpl. 2003, 3, 74-78.
18. Weclawiack, H.; Kamar, N.; Mehrenberger, M.; Guilbeau-Frugier, C.; Modesto, A.; Izopet, J.; Ribes, D.; Sallusto, F.; Rostaing, L. α-Interferon therapy for chronic hepatitis C may induce acute allograft rejection in kidney transplant patients with failed allografts. Nephrol. Dial. Transpl. 2008, 23, 1043-1047.
19. Khatri, A.; Dutta, S.; Marbury, T.; Preston, R.A.; Rodrigues, L.; Wang, H.; Awni, W.; Menon, R. The pharmacokinetics and safety of the direct acting antiviral regimen of ABT-450/r, ombitasvir with/without dasabuvir in subjects with mild, moderate and severe renal impairment compared to subjects with normal renal function. In Proceedings of the AASLD 2014, Boston, MA, USA, 7-11 November 2014.
20. Pockros, P.J.; Reddy, K.R.; Mantry, P.S.; Cohen, E.; Bennett, M.; Sulkowski, M.S.; Bernstein, D.; Podsadecki, T.; Cohen, D.; Shulman, N.S. Safety of Ombitasvir/paritaprevir/ritonavir plus dasabuvir for treating HCV GT1 infection in patients with severe renal impairment or end-stage renal disease: The RUBY-I-Study. In Proceedings of the EASL 2015, Vienna, Austria, 22-26 April 2015.
21. Gane, E.; Robson, R.; Bonacini, M.; Maliakkal, B.; Kirby, B.; Liu, L.; Sajwani, K.; Stamm, L.M.; Brainard, D.M.; McHutchison, J.G.; et al. Safety, antiviral efficacy, and pharmacokinetics of sofosbuvir in patients with severe renal impairment. In Proceedings of the AASLD 2014, Boston, MA, USA, 7-11 November 2014.
22. Roth, D.; Nelson, D.; Bruchfeld, A. Liapakis, A.; Silva, M.; Monsour, H., Jr.; Martin, P.; Pol, S.; Londoño, M.-C.; Hassanein, T.; et al. C-SURFER: Grazoprevir plus Elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease. In Proceedings of the EASL 2015, Vienna, Austria, 22-26 April 2015.
23. Saxena, V.; Koraishy, F.M. Safety and efficacy of sofosbuvir-containing regimens in hepatitis C infected patients with reduced renal function: Real-world experience from HCV-target. In Proceedings of the EASL 2015, Vienna, Austria, 22-26 April 2015.
24. Afdhal, N.; Everson, G.T.; Calleja, J.L.; McCaughan, G.; Bosch, J.; Denning, J.; Brainard, D.M.; McHutchison, J.G.; Brandt-Sarif, T.; An, D.; et al. Effect of long-term viral suppression with sofosbuvir + ribavirin on hepatic venous pressure gradient in HCV-infected patients with cirrhosis and portal hypertension. In Proceedings of the EASL 2015, Vienna, Austria, 22-26 April 2015.
25. Manns, M.; Forns, X.; Samuel, D.; Denningemail, J.; Arterburn, S.; Brandt-Sarif, T.; Dvory-Sobol, H.; Pang, P.S.; McHutchison, J.G.; Gane, E.; et al. Ledipasvir/sofosbuvir with ribavirin is safe and efficacious in decompensated and post liver transplantation patients with HCV infection: Preliminary results of the prospective SOLAR 2 trial. In Proceedings of the EASL 2015, Vienna, Austria, 22-26 April 2015.
26. Poordad, F.; Schiff, E.R.; Vierling, J.M.; Landis, C.; Fontana, R.J.; Yang, R.; McPhee, F.; Hughes, E.A.; Noviello, S.; Swenson, E.S. Daclatasvir, sofosbuvir and ribavirin combination for HCV patients with advanced cirrhosis or posttransplant recurrence: Phase 3 ALLY-1 STUDY. In Proceedings of the EASL 2015, Vienna, Austria, 22-26 April 2015.
27. Lawitz, E.; Poordad, F. Simeprevir (SMV) plus Daclatasvir (DCV) anf Sofosbuvir (SOF) in treatment-naïve and-Experienced patients with chronic hepatitis C virus genotype 1 or 4 infection and decompensated liver disease: Interim results from the phase II impact study. In Proceedings of the EASL 2015, Vienna, Austria, 22-26 April 2015.
28. Mantry, P.S.; Kwo, P.; Coakley, E. Te, H.; Vargas, H.; Brown, R.S., Jr.; Gordon, F.; Levitsky, J.; Terrault, N.; Burton, J., Jr.; et al. High sustained virologic response rates in liver transplant recipients with recurrent HCV genotype 1 infection geceiving ABT-450/r/ombitasvir + dasabuvir plus ribavirin. In Proceedings of the AASLD 2014, Boston, MA, USA, 7-11 November 2014.
29. Reddy, K.R.; Everson, G.; Flamm, S.L.; Denning, J.M.; Arterburn, S.; Brandt-Sarif, T.; Pang, P.S.; Dvory-Sobol, H.; McHutchison, J.G.; Curry, M.P.; et al. Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with post-transplant recurrence: Preliminary results of a prospective, multicenter study. In Proceedings of the AASLD 2014, Boston, MA, USA, 7-11 November 2014.
30. Forns, X.; Berenguer, M.; Herzer, K.; Sterneck, M.; Donato, M.F.; Andreone, P.; Fagiuoli, S.; Cieciura, T.; Durlik, M.; Calleja, J.L.; et al. On-treatment virologic response and tolerability of simeprevir, daclatasvir and ribavirin in patients with recurrent hepatitis c virus genotype 1b infection after orthotopic liver transplantation (OLT): Interim data from the phase II Saturn study. In Proceedings of the EASL 2015, Vienna, Austria, 22-26 April 2015.
31. Tischer, S.; Fontana, R.J. Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting. J. Hepatol. 2014, 60, 872-884.
32. German, P.; Pang, P.S.; Fang, L.; Chung, D. Drug-Drug interaction profile of the fixed-dose combination tablet ledipasvir/sofosbuvir. In Proceedings of the AASLD 2014, Boston, MA, USA, 7-11 November 2014.
33. Forns, X.; García-Retortillo, M.; Serrano, T.; Feliu, A.; Suarez, F.; de la Mata, M.; García-Valdecasas, J.C.; Navasa, M.; Rimola, A.; Rodés, J. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J. Hepatol. 2003, 39, 389-396.
34. Everson, G.T.; Trotter, J.; Forman, L.; Kugelmas, M.; Halprin, A.; Fey, B.; Ray, C. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005, 42, 255-262.
35. Carrion, J.A.; Martínez-Bauer, E.; Crespo, G.; Ramírez, S.; Pérez-del-Pulgar, S.; García-Valdecasas, J.C.; Navasa, M.; Forns, X. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study. J. Hepatol. 2009, 50, 719-728.
36. Crespo, G.; Mariño, Z.; Navasa, M.; Forns, X. Viral hepatitis in liver transplantation. Gastroenterology 2012, 142, 1373-1383.
37. Pawlotsky, J.M.; Aghemo, A.; Back, D. EASL Recommendations on Treatment of Hepatitis C 2015. In Proceedings of the EASL 2015, Vienna, Austria, 22-26 April 2015.
38. Foster, G.R.; McLauchlan, J.; Irving, W.; Cheung, M.; Hudson, B.; Verma, S.; Agarwal, K.; HCV Research UK EAP Group. Treatment of decompensated HCV cirrhosis in patients with diverse genotypes: 12 weeks sofosbuvir and NS5A inhibitors with/without ribavirin is effective in HCV Genotypes 1 and 3. In Proceedings of the EASL 2015, Vienna, Austria, 22-26 April 2015.
39. Hezode, C..; de Ledinghen, V.; Fontaine, H. Daclatasvir plus sofosbuvir with or without ribavirin in patients with HCV genotype 3 infection: Interim analysis of a French multicentre compassionate use program. In Proceedings of the EASL 2015, Vienna, Austria, 22-26 April 2015
40. Reau, N.; Fried, M.W.; Wedemeyer, H.; Cooper, C.; Diago, M.; Craxi, A.; Strasser, S.; DuFour, J.-F.; Xie, W.; Larsen, L.; et al. High SVR rates despite multiple negative predictors in genotype 1 patients receiving ombitasvir/paritaprevir/r, dasabuvir with or without ribavirin for 12 and 24 weeks: Integrated analysis of six phase 3 trials. In Proceedings of the EASL 2015, Vienna, Austria, 22-26 April 2015.
41. Wedemeyer, H.; Berg, T.; Flamm, S.L.; Foster, G.R.; Craxi, A.; Larrey, D.; Morgan, T.R.; Fried, M.W.; Poordad, F.; Trinh, R.; et al. Improvement in liver function and non-invasive estimates of liver fibrosis 48 weeks after treatment with ombitasvir/paritaprevir/r, dasabuvir, and ribavirin in HCV genotype 1 patients with cirrhosis. In Proceedings of the EASL 2015, Vienna, Austria, 22-26 April 2015.
42. Reddy, R.R.; Lim, J.K.; Kuo, A.; Di Bisceglie, A.M.; Vargas, H.E.; Galati, J.S.; Morelli, G.; Everson, G.T.; Kwo, P.; Brown, R.S.; et al. All oral HCV therapy is safe and effective in patients with decompensated cirrhosis: Report from HCV-TARGET. In Proceedings of the EASL 2015, Vienna, Austria, 22-26 April 2015.
43. Dieterich, D.; Bacon, B.; Flamm, S.; Kowdley, K.; Milliganemail, S.; Tsai, N.; Younossi, Z.; Lawitz, E. Final evaluation of 955 HCV patients treated with 12 week regimens containing sofosbuvir +/− simeprevir in the trio network: Academic and community treatment of a real-world, heterogenous population. In Proceedings of the EASL 2015, Vienna, Austria, 22-26 April 2015.
44. Kim, W.R.; Terrault N.A.; Pedersen, R.A.; Therneau, T.M.; Edwards, E.; Hindman, A.A.; Brosgart, C.L. Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. Gastroenterology 2009, 137, 1680-1686.
45. Thuluvath, P.J.; Guidinger, M.K.; Fung, J.J.; Johnson, L.B.; Rayhill, S.C.; Pelletier, S.J. Liver transplantation in the United States, 1999-2008. Am. J. Transpl. 2010, 10, 1003-1019.
46. Berenguer, M.; Prieto, M.; Rayón, J.M.; Mora, J.; Pastor, M.; Ortiz, V.; Carrasco, D.; San Juan, F.; Burgueño, M.D.; Mir, J.; et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000, 32, 852-858.
47. Berenguer, M.; Palau, A.; Aguilera, V.; Rayón, J.M.; Juan, F.S.; Prieto, M. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am. J. Transpl. 2008, 8, 679-687.
48. Gurusamy, K.S.; Tsochatzis, E.; Toon, C.D.; Xirouchakis, E.; Burroughs, A.K.; Davidson, B.R. Antiviral interventions for liver transplant patients with recurrent graft infection due to hepatitis C virus. Cochrane Database Syst. Rev. 2013, 12, doi:10.1002/14651858.CD006803.pub4.
49. Xirouchakis, E.; Triantos, C.; Manousou, P.; Sigalas, A.; Calvaruso, V.; Corbani, A.; Leandro, G.; Patch, D.; Burroughs, A. Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: Systematic review and meta-analysis of prospective controlled studies. J. Viral Hepat. 2008, 15, 699-709.
50. Brown, R.S.; Reddy, K.R.; O'Leary, J.G. Safety and efficacy of new DAA-based therapy for hepatitis C post-transplant: Interval results from the HCV-TARGET longitudinal, observational study. In Proceedings of the AASLD 2014, Boston, MA, USA, 7-11 November 2014.